A Randomized, Open-label Study of the Effect of Intermittent Xeloda in Combination With Eloxatin, Versus Fluorouracil/Leucovorin, on Disease-free Survival in Patients Who Have Undergone Surgery for Colon Cancer.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Disease-free Survival (DFS) [Number of Events]
Number of patients with/without recurrence of the original colon cancer or appearance of a new colon or rectal cancer, or death due to any cause. Based on tumor assessments and survival follow-up assessments.
Time from randomization date to date of first event/date last known to be event free. Median observation time for DFS was approx 57 mos.
No
Clinical Trials
Study Director
Hoffmann-La Roche
United States: Food and Drug Administration
NO16968
NCT00069121
January 2003
January 2012
Name | Location |
---|---|
Hinsdale, Illinois 60521 | |
New Britain, Connecticut 06052 | |
Bettendorf, Iowa 52722 | |
Alexandria, Minnesota 56308 | |
Albany, Georgia 31701 | |
Great Falls, Montana 59405 | |
Birmingham, Alabama 35294 | |
Phoenix, Arizona 85012 | |
Fountain Valley, California 92708 | |
Miami, Florida 33176 | |
Columbia, Missouri 65203 | |
Albany, New York 12208 | |
Philadelphia, Pennsylvania 19104 | |
Nashville, Tennessee 37203-1632 | |
Austin, Texas 78705 | |
Seattle, Washington 98195 | |
Flint, Michigan 48532 | |
Hackensack, New Jersey 07601 | |
Albuquerque, New Mexico 87131-5636 | |
Metairie, Louisiana 70006 | |
Denver, Colorado | |
Charlotte, North Carolina | |
Milwaukee, Wisconsin | |
Indianapolis, Indiana | |
Charleston, South Carolina | |
Lebanon, New Hampshire | |
Washington, District of Columbia | |
Las Vegas, Nevada 89109 | |
Salt Lake City, Utah 84112 | |
Coeur D'alene, Idaho 83814 |